News

Parents and pediatricians navigate the complexities of neurodiversity, emphasizing the need for open communication and better resources for child development.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The FDA approves gardenia (genipin) blue as a natural food color, enhancing options for manufacturers and supporting the shift away from synthetic dyes.

A study reveals declining US neonatal mortality overall, yet highlights rising deaths from fetal malnutrition, emphasizing ongoing disparities in neonatal health outcomes.

Wearable-derived biorhythms predicted postoperative complications in children up to 3 days early, offering a new tool for remote pediatric monitoring.

The nitric oxide–releasing topical is the first prescription medication approved for at-home treatment of molluscum contagiosum.

A clinical trial found CBD was safe and well-tolerated in autistic boys, with some showing behavioral improvements, though placebo effects were strong.

Cancer-specific summer camps empower children with cancer, fostering community, emotional healing, and safe fun, while providing families much-needed respite and support.

Even low-level lead exposure in early childhood may speed up memory loss, according to a new study using a cognitive task to measure forgetting rates.

His vital signs in clinic were within normal limits, and the only additional finding at this time was a nontender, nonpruritic, and nonpalpable petechial rash on the bilateral lower extremities.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

A week into July 2025, the total reported cases in the United States have surpassed the peak of 1274 cases recorded for all 2019.

Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

A roundup of the most impactful FDA approvals in pediatric health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

A look back at the most important FDA approvals, clinical research, and expert perspectives shaping pediatric health care in the first half of 2025.

The American Academy of Pediatrics warns families to avoid home fireworks and offers safer alternatives to prevent injuries, especially in young children.

View our Q2 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Additionally, long sleep duration could be associated with increased odds of being reliably symptomatic at 4 weeks.

Data from the study suggest caretakers of CPP patients be vigilant for psychiatric symptoms to begin care at an early stage.

Take a quick look at everything you may have missed last month, including the top FDA approvals and latest clinical updates.

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.

The updated labeling includes a new contraindication for patients with prior or active hepatic events.

MNV-201 is being evaluated in phase 2 clinical trials for treatment of the ultra-rare, life-threatening mitochondrial disorder affecting children.